Despite significant advances in cancer diagnosis and treatment, tumor recurrence, metastasis, and drug resistance remain major clinical challenges. These ...

Q1 2025 Earnings Call Transcript May 19, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.08 EPS, ...

Precious metal complexes play a crucial role in the development of medical treatments, particularly in oncology. However, ...

AB Science S.A. (the " Company ” or " AB Science ”, Euronext - FR0010557264 - AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.8 million subscribed ...

Mediated Inflammation that Promotes Cancer Initiation and/or Progression", we are pleased to announce the launch of ...

Agilent Technologies and Ubix Therapeutics have signed a Memorandum of Understanding (MOU) to accelerate research and developmen ...

This came after AstraZeneca Pharma India presented the proposal for a grant of permission to import and market Osimertinib ...

The demand for the widely used cancer drug Taxol is increasing, but it's difficult and expensive to produce because it hasn't been possible to do it biosynthetically. Until now, that is. Researchers ...

Compugen Ltd (CGEN) showcases strong cash position and promising clinical trials despite a dip in quarterly revenue.